Obinutuzumab, CAS 949142-50-1

Product Description: Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42./[2]Dalle S, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody -GA101. Mol Cancer Ther. 2011 Jan;10(1):178-85./[3]Herting F, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab(GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014 Sep;55(9):2151-5160.

CAS Number: 949142-50-1

Molecular Weight: 146298.97

Compound Purity: 99.4

Research Area: Cancer

Solubility: H2O

Target: CD20

• SKU: MEXHY-P9910-5
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-P9910-5
• Green Labware: No
• Package Unit: 5 mg
• Quantity Unit: STK